Biomind Labs Past Earnings Performance
Past criteria checks 0/6
Biomind Labs has been growing earnings at an average annual rate of 128.3%, while the Pharmaceuticals industry saw earnings growing at 43.8% annually.
Key information
128.3%
Earnings growth rate
147.2%
EPS growth rate
| Pharmaceuticals Industry Growth | 23.1% |
| Revenue growth rate | n/a |
| Return on equity | n/a |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2023 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Biomind Labs makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 23 | 0 | -1 | 1 | 1 |
| 30 Jun 23 | 0 | -2 | 2 | 1 |
| 31 Mar 23 | 0 | -3 | 2 | 1 |
| 31 Dec 22 | 0 | -3 | 2 | 1 |
| 30 Sep 22 | 0 | -4 | 3 | 1 |
| 30 Jun 22 | 0 | -5 | 4 | 1 |
| 31 Mar 22 | 0 | -5 | 3 | 1 |
| 31 Dec 21 | 0 | -4 | 3 | 1 |
| 31 Mar 21 | 0 | -37 | 1 | 36 |
Quality Earnings: BMND is currently unprofitable.
Growing Profit Margin: BMND is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if BMND's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare BMND's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BMND is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-40.8%).
Return on Equity
High ROE: BMND's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.